Literature DB >> 25059817

Preconceptual Folic Acid Use and Recurrence Risk Counseling for Congenital Heart Disease.

Shabnam Peyvandi1, Jack Rychik2,3,4, Xuemei Zhang5,3,4, Judy A Shea6,4, Elizabeth Goldmuntz2,3,4.   

Abstract

OBJECTIVE: Recurrence risk of congenital heart disease (CHD) in families with an affected first-degree relative is increased as compared with the general population. Advances in genetic testing and evidence that preconceptual folic acid supplementation may decrease risk of CHD warrant preventative counseling for at-risk families. Our goal was to document patterns of preconceptual folic acid supplementation and recurrence risk counseling in at-risk families in order to identify opportunities for improved preventative care.
DESIGN: Mothers referred for a fetal echocardiogram were prospectively enrolled. Cases were defined as mothers deemed to be at higher risk of having an affected fetus with CHD given an affected parent or affected previous pregnancy with CHD. Controls were defined as mothers with no prenatal risk factors. Mothers completed a validated questionnaire assessing use of folic acid supplementation and receipt of recurrence risk counseling. Chi-square analyses were performed to analyze questionnaire responses and demographic data.
RESULTS: A total of 314 subjects participated (controls = 216, cases = 98). Cases took preconceptual folic acid supplementation more often than controls (P < .001), but only 55% started preconceptually. Maternal advanced education and counseling (P < .001) were associated with preconceptual supplementation, whereas complexity of CHD in the relative was not. While 70% of cases received some recurrence risk counseling, those with advanced education and complex CHD in the affected relative were more likely to receive counseling. Few at-risk cases interacted with genetic services (19%).
CONCLUSIONS: At-risk mothers with lower education are less likely to take preconceptual folic acid supplementation or receive recurrence risk counseling. Health care providers should proactively provide this information to all at-risk patients and develop collaborations with genetic services.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  Congenital Heart Disease; Folic Acid Supplementation; Recurrence Risk; Risk Factors

Mesh:

Substances:

Year:  2014        PMID: 25059817      PMCID: PMC4762601          DOI: 10.1111/chd.12206

Source DB:  PubMed          Journal:  Congenit Heart Dis        ISSN: 1747-079X            Impact factor:   2.007


  27 in total

1.  Update on counseling the family with a first-degree relative with a congenital heart defect.

Authors:  J J Nora; A H Nora
Journal:  Am J Med Genet       Date:  1988-01

2.  Periconceptional multivitamin use and the occurrence of conotruncal heart defects: results from a population-based, case-control study.

Authors:  L D Botto; M J Khoury; J Mulinare; J D Erickson
Journal:  Pediatrics       Date:  1996-11       Impact factor: 7.124

3.  Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation.

Authors:  A E Czeizel
Journal:  Am J Med Genet       Date:  1996-03-15

Review 4.  The geneticist's role in adult congenital heart disease.

Authors:  Francois P Bernier; Renee Spaetgens
Journal:  Cardiol Clin       Date:  2006-11       Impact factor: 2.213

5.  Do multivitamin or folic acid supplements reduce the risk for congenital heart defects? Evidence and gaps.

Authors:  Lorenzo D Botto; Joseph Mulinare; J David Erickson
Journal:  Am J Med Genet A       Date:  2003-08-30       Impact factor: 2.802

6.  Familial risks of congenital heart defect assessed in a population-based epidemiologic study.

Authors:  J A Boughman; K A Berg; J A Astemborski; E B Clark; R J McCarter; J D Rubin; C Ferencz
Journal:  Am J Med Genet       Date:  1987-04

7.  Recurrence risks in offspring of adults with major heart defects: results from first cohort of British collaborative study.

Authors:  J Burn; P Brennan; J Little; S Holloway; R Coffey; J Somerville; N R Dennis; L Allan; R Arnold; J E Deanfield; M Godman; A Houston; B Keeton; C Oakley; O Scott; E Silove; J Wilkinson; M Pembrey; A S Hunter
Journal:  Lancet       Date:  1998-01-31       Impact factor: 79.321

8.  Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation.

Authors:  A E Czeizel; I Dudás
Journal:  N Engl J Med       Date:  1992-12-24       Impact factor: 91.245

9.  Congenital heart disease caused by mutations in the transcription factor NKX2-5.

Authors:  J J Schott; D W Benson; C T Basson; W Pease; G M Silberbach; J P Moak; B J Maron; C E Seidman; J G Seidman
Journal:  Science       Date:  1998-07-03       Impact factor: 47.728

10.  Congenital heart disease: prevalence at livebirth. The Baltimore-Washington Infant Study.

Authors:  C Ferencz; J D Rubin; R J McCarter; J I Brenner; C A Neill; L W Perry; S I Hepner; J W Downing
Journal:  Am J Epidemiol       Date:  1985-01       Impact factor: 4.897

View more
  1 in total

1.  Utilization of preconception care and associated factors in Hosanna Town, Southern Ethiopia.

Authors:  Meron Admasu Wegene; Negeso Gebeyehu Gejo; Daniel Yohannes Bedecha; Amene Abebe Kerbo; Shemsu Nuriye Hagisso; Solomon Abrha Damtew
Journal:  PLoS One       Date:  2022-01-07       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.